In vitro and in vivo stability a Cryptococcus neoformans glucuronoxylomannan epitope that elicits protective antibodies

Infection and Immunity

Volumn 67, Issue 6, 1999, Pages 3096-3107

  Cleare, Wendy ^a   Cherniak, Robert ^b   Casadevall, Arturo ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; MANNAN; OPSONIN;

ACETYLATION; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; IMMUNOFLUORESCENCE; MALE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SEROTYPE; VIRULENCE;

EID: 0032982781     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.6.3096-3107.1999     Document Type: Article

References (57)

1. Belay, T., and R. Cherniak. 1995. Determination of antigen binding specificities of Cryptococcus neoformans factor sera by enzyme-linked immunosorbent assay. Infect. Immun. 63:1810-1819.
2. Buchanan, K. L., and J. W. Murphy. 1998. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis. 4:71-83.
3. Casadevall, A. 1995. Antibody immunity and invasive fungal infections. Infect. Immun. 63:4211-4218.
4. Casadevall, A., W. Cleare, M. Feldmesser, A. Glatman-Freedman, D. L. Goldman, T. R. Kozel, N. Lendvai, J. Mukherjee, L. Pirofski, J. Rivera, A. L. Rosas, M. D. Scharff, P. Valadon, K. Westin, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. Antimicrob. Agents Chemother. 42:1437-1446.
5. Casadevall, A., J. Mukherjee, S. J. M. Devi, R. Schneerson, J. B. Robbins, and M. D. Scharff. 1992. Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J. Infect. Dis. 65:1086-1093.
6. Cherniak, R., L. C. Morris, B. C. Anderson, and S. A. Meyer. 1991. Facilitated isolation, purification, and analysis of glucuronoxylomannan of Cryptococcus neoformans. Infect. Immun. 59:59-64.
7. Cherniak, R., L. C. Morris, T. Belay, E. D. Spitzer, and A. Casadevall. 1995. Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect. Immun. 63:1899-1905.
8. 13C-nuclear magnetic resonance spectroscopy. Carbohydr. Res. 225:331-337.
9. 13C-nuclear magnetic resonance spectroscopy. Carbohydr. Res. 223:263-269.
10. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507-1512.
11. 1H NMR spectra of glucuronoxylomannans using a computer-stimulated artificial neural network. Clin. Diagn. Lab. Immunol. 5:146-159.
12. Cleare, W., and A. Casadevall. 1998. The different binding patterns of two IgM monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlates with serotype classification and differences in functional assays. Clin. Diagn. Lab. Immunol. 5:125-129.
13. Cleare, W., and A. Casadevall. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release. Med. Mycol., in press.
14. Cleare, W., S. Mukherjee, E. D. Spitzer, and A. Casadevall. 1994. Prevalence in Cryptococcus neoformans strains of a polysaccharide epitope which can elicit protective antibodies. Clin. Diagn. Lab. Immunol. 1:737-740.
15. Currie, B., H. Sanati, A. S. Ibrahim, J. E. Edwards, A. Casadevall, and M. A. Ghannoum. 1995. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage. Antimicrob. Agents Chemother. 30:1934-1937.
16. Currie, B. P., L. F. Freundlich, M. A. Soto, and A. Casadevall. 1993. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J. Clin. Microbiol. 31: 2519-2522.
17. Curtiss, R., III, C. Pearce, J. Pollack, and H. M. Murchison. 1987. Isolation and characterization of mutants of Streptococcus mutans using selective removal of wild-type cells by agglutination with an agglutinin from Persea americana. Acta Microbiol. Pol. 36:3-15.
18. Devi, S. J. N. 1996. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 14:841-842.
19. Diamond, R. D., and J. E. Bennett. 1973. Growth of Cryptococcus neoformans within human macrophages in vitro. Infect. Immun. 7:231-236.
20. Dixon, D. M., A. Casadevall, B. Klein, L. R. Travassos, and G. Deep. 1998. Development of vaccines and their use in the prevention of fungal infections. Med. Mycol. 36(Suppl.):57-67.
21. Dromer, F., J. Salamero, A. Contrepois, C. Carbon, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:742-748.
22. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55:1895-1899.
23. Feldmesser, M., and A. Casadevall. 1998. Mechanism of action of antibody to capsular polysaccharide in Cryptococcus neoformans infection. Front. Biosci. 3:135-151.
24. Franzot, S. P., J. Mukherjee, R. Cherniak, L Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89-97.
25. Frasa, H., J. Procee, R. Torensma, A. Verbruggen, A. Algra, M. Rozenberg-Arska, K. Kraaijeveld, and J. Verhoef. 1993. Eschenchia coli in bacteremia: O-acetylated K1 strains appear to be more virulent than non-O-acetylated K1 strains. J. Clin. Microbiol. 31:3174-3178.
26. Fries, B. C., and A. Casadevall. 1998. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J. Infect. Dis. 178:1761-1788.
27. Fries, B. C., F. Chen, B. P. Currie, and A. Casadevall. 1996. Karyotype instability in Cryptococcus neoformans infection. J. Clin. Microbiol. 34:1531-1534.
28. Fujihara, H., K. Kagaya, and Y. Fukazawa. 1997. Anti-chemotactic activity of capsular polysaccharide of Cryptococcus neoformans in vitro. Microbiol. Immunol. 41:657-664.
29. Goldman, D. L., B. C. Fries, S. P. Franzot, L. Montella, and A. Casadevall. 1998. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Natl. Acad. Sci. USA 95:14967-14972.
30. Granger, D. L., J. R. Perfect, and D. T. Durack. 1985. Virulence of Cryptococcus neoformans. Regulation of capsule synthesis by carbon dioxide. J. Clin. Investig. 76:508-516.
31. Griffin, F. M., J. A. Griffin, J. E. Leider, and S. C. Silverstein. 1975. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J. Exp. Med. 142:1263-1282.
32. Kozel, T. R. 1983. Dissociation of a hydrophobic surface from phagocytosis of encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 39:1214-1219.
33. Kozel, T. R. 1995. Virulence factors of Cryptococcus neoformans. Trends Microbiol. 3:295-299.
34. Kozel, T. R., E. Reiss, and R. Cherniak. 1980. Concomitant but not casual association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide. Infect. Immun. 29:295-300.
35. Lambkin, R., and L. McLain. 1994. Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift. J. Gen. Virol. 75:3493-3502.
36. Levitz, S. M., and T. P. Farrell. 1990. Growth inhibition of Cryptococcus neoformans by cultured human monocytes: role of the capsule, opsonins, the culture surface, and cytokines. Infect. Immun. 58:1201-1209.
37. Lyman, C. A., S. J. Devi, J. Nathanson, C. E. Frasch, P. A. Plzzo, and T. J. Walsh. 1995. Detection and quantitation of the glucuronoxylomannan-like polysaccharide antigen from clinical and nonclinical isolates of Trichosporon beigelii and implications for pathogenicity. J. Clin. Microbiol. 33:126-130.
38. Mai, G., W. K. Seow, G. B. Pier, J. G. McCormack, and Y. H. Thong. 1993. Suppression of lymphocyte and neutrophil functions by Pseudomonas aeruginosa mucoid exopolysaccharide (alginate): reversal by physicochemical, alginase, and specific monoclonal antibody treatments. Infect. Immun. 61:559-564.
39. Mukherjee, J., W. Cleare, and A. Casadevall. 1995. Monoclonal antibody mediated capsular reactions (quellung) in Cryptococcus neoformans. J. Immunol. Methods 184:139-143.
40. Mukherjee, J., G. Nussbaum, M. D. Scharf, and A. Casadevall. 1995. Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell. J. Exp. Med. 181:405-409.
41. Mukherjee, J., M. D. Scharff, and A. Casadevall. 1992. Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60:4534-4541.
42. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573-579.
43. Nosanchuk, J. D., and A. Casadevall. 1997. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect. Immun. 65:1836-1841.
44. Nussbaum, G., W. Cleare, A. Casadevall, M. D. Scharf, and P. Valadon. 1997. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J. Exp. Med. 185:685-697.
45. Otteson, E. W., W. H. Welch, and T. R. Kozel. 1994. Protein-polysaccharide interactions. A monoclonal antibody specific for the capsular polysaccharide of Cryptococcus neoformans. J. Biol. Chem. 269:1858-1864.
46. Pirofski, L., and A. Casadevall. 1996. Antibody immunity to Cryptococcus neoformans: paradigm for antibody immunity to the fungi? Zentbl. Bakteriol. 284:475-495.
47. Pirofski, L., R. Lui, M. DeShaw, A. B. Kressel, and Z. Zhong. 1995. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. Infect. Immun. 63:3005-3014.
48. Sanford, J. E., D. M. Lupan, A. M. Schlagetter, and T. R. Kozel. 1990. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide. Infect. Immun. 58:1919-1923.
49. Slauch, J. M., M. J. Mahan, P. Michetti, M. R. Neutra, and J. J. Mekalanos. 1995. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect. Immun. 63:437-441.
50. Spiropulu, C., R. A. Eppard, E. Otteson, and T. R. Kozel. 1989. Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide. Infect. Immun. 57: 3240-3242.
51. Takegawa, K., N. Tanaka, M. Tabuchi, and S. Iwahara. 1996. Isolation and characterization of a glycosylation mutant from Schizosaccharomyces pombe. Biosci. Biotechnol. Biochem. 60:1156-1159.
52. Todaro-Luck, F., E. Reiss, R. Cherniak, and L. Kaufman. 1989. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies. Infect. Immun. 57:3882-3887.
53. Vecchiarelli, A., and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149:321-333.
54. Wang, Y., and A. Casadevall. 1994. Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect. Immun. 64:3004-3007.
55. Young, B. J., and T. R. Kozel. 1993. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 61:2966-2972.
56. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharf. 1995. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol. 154:1810-1816.
57. Zahringer, U., Y. A. Knirel, B. Lindner, J. H. Helbig, A. Sonesson, R. Marre, and E. T. Rietschel. 1995. The lipopolysaccharide of Legionella pneumophila serogroup 1 (strain Philadelphia 1): chemical structure and biochemical significance. Prog. Clin. Biol. Res. 292:113-139.